Ser237
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser237  -  BVR (human)

Site Information
sFHFksGsLENVPNV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4774274

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 3 ) , immunoprecipitation ( 3 ) , mass spectrometry ( 1 , 2 , 3 , 4 ) , mass spectrometry (in vitro) ( 3 )
Disease tissue studied:
lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 4 ) , HEK293-A (epithelial) ( 3 ) , HeLa (cervical) ( 1 ) , lung ( 2 )

Upstream Regulation
Putative in vivo kinases:
PKCD (human) ( 3 )
Kinases, in vitro:
PKCD (human) ( 3 )

Downstream Regulation
Effects of modification on BVR:
enzymatic activity, induced ( 3 )

References 

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

3

Miralem T, et al. (2012) The human biliverdin reductase-based peptide fragments and biliverdin regulate protein kinase Cδ activity: the peptides are inhibitors or substrate for the protein kinase C. J Biol Chem 287, 24698-712
22584576   Curated Info

4

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.